Meghan Dickman, M.D., is Clinical Assistant Professor of Dermatology and Medical Director of Dermatology at Stanford ValleyCare. Dr. Dickman earned her B.S., with distinction, from the University of Michigan in 2006. She received her medical degree from the University of California, San Francisco. During medical school, Dr. Dickman was inducted into the Alpha Omega Alpha Honor Medical Society. She completed her dermatology residency at Stanford University and served as Chief Resident in her final year. She is board certified in dermatology by the American Board of Dermatology. Her professional focus is general medical dermatology, including acne, psoriasis, skin cancer, and dermatologic surgery. She also has a special interest in patient access and community outreach as well as medical education.
- Skin Cancer
- Dermatologic Surgery
Clinical Assistant Professor, Dermatology
Residency:Stanford University Dept of Dermatology (2016) CA
Internship:California Pacific Medical Center Internal Medicine Residency (2013) CA
Board Certification: Dermatology, American Board of Dermatology (2016)
Medical Education:University of California San Francisco (2012) CA
Treatment of keratitis-ichthyosis-deafness (KID) syndrome in children: a case report and review of the literature
2015; 28 (2): 89-93
Keratitis-ichthyosis-deafness (KID) syndrome is a rare hereditary cornification disorder resulting from mutations in connexin 26, a protein important for intercellular communication. In addition to the characteristic clinical triad of congenital bilateral sensorineural hearing loss, keratitis, and erythrokeratoderma, affected individuals also suffer from chronic bacterial and fungal infections and have an increased risk of benign and malignant cutaneous tumors. Treatments with antibiotics, antifungals, and systemic retinoids have been reported with variable response. Ocular and skeletal toxicity from prolonged exposure to systemic retinoids is a major concern especially in children. We report a case of a 7-year-old boy with KID syndrome complicated by frequent infections who responded well to acitretin 0.5-1.0 mg/kg/day. The patient had significant improvement of the hyperkeratosis on the scalp, trunk, and extremities within 4 weeks after initiating treatment. The patient has been on treatment for over a year without notable ocular, skeletal, or laboratory side effects. A review of the literature focusing on therapeutic options for KID syndrome and concerns about safety and tolerability is presented.
View details for DOI 10.1111/dth.12192
View details for Web of Science ID 000352630800010
Aspirin Therapy in Venous Malformation: A Retrospective Cohort Study of Benefits, Side Effects, and Patient Experiences
2014; 31 (5): 556-560
Venous malformations (VMs) are often painful and may enlarge over time. Chronic coagulopathy is common in VMs and may contribute to phleboliths and potentially to disease progression. Few studies have examined the effects of anticoagulation on VMs and to our knowledge none have examined the use of aspirin therapy. A survey was administered to patients and parents of patients with VMs who attended the University of California at San Francisco Vascular Anomalies Center over a 4-year period (2008-2012) to whom aspirin had been recommended. They were surveyed regarding whether they were taking aspirin and, if yes, whether aspirin had resulted in any appreciable benefit. Sixty-five letters were sent to potential subjects: 38 participated and 27 declined to participate or could not be contacted. Twenty-eight of the 38 had begun aspirin and 22 reported current use. Seventeen reported some benefit, including less aching (n = 2), less shooting pain (n = 15), less fullness and swelling (n = 13), and shrinking of the VM (n = 1). Discontinuation of aspirin was associated with worsening VM symptoms in five of six patients. Side effects were reported in 6 of 28 patients, including five episodes of minor bleeding or excessive bruising and one of nausea and vomiting. This study suggests that aspirin may be a beneficial treatment for VM, with a reduction in pain and soft tissue swelling and an acceptable side-effect profile, but the retrospective nature of the study and the small size of the cohort limited our conclusions. Larger prospective studies of aspirin for VM using clinical and laboratory outcome measures are needed to confirm these observations.
View details for DOI 10.1111/pde.12373
View details for Web of Science ID 000341811700004
View details for PubMedID 25040175
- Visual diagnosis: 13-year-old girl with pink papules. Allergic contact dermatitis with id reaction. Pediatrics in review 2013; 34 (6): e22-4
Sacrococcygeal Teratoma Masquerading as Congenital Hemangioma
2013; 30 (1): 112-116
Sacrococcygeal teratoma (SCT) is a rare tumor, present in approximately one in 40,000 live births. A small proportion of SCT have malignant potential, so prompt recognition and surgical resection are necessary. We report two cases of SCT initially misdiagnosed as hemangiomas because of their cutaneous appearance and in particular vascular stains overlying soft tissue mass. These two cases emphasize that SCT should be considered in the differential diagnosis of hemangiomas and in particular of congenital hemangiomas.
View details for DOI 10.1111/j.1525-1470.2011.01703.x
View details for Web of Science ID 000313727700018
View details for PubMedID 22353016
- The Relationship Between Hygiene and Microbial Burden in Atopic Dermatitis Risk Based on a Systematic Review ARCHIVES OF DERMATOLOGY 2012; 148 (8): 936-938